Navigation

Hepatitis B - entecavir: costing statement

A costing statement has been produced by NICE to provide an implementation tool to estimate the financial impact to the NHS of implementing the technology appraisal TA153-Entecavirfor the treatment of chronic hepatitis B. The Institute would welcome feedback from users to inform the development of future templates. Please email your comments to costing@nice.org.uk

This page was last updated: 02 January 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.